Fisher K, Grafton F, Ispaso F, Tworig J, Derler R, Sonntag F
Mol Ther Methods Clin Dev. 2025; 33(1):101412.
PMID: 39968185
PMC: 11834096.
DOI: 10.1016/j.omtm.2025.101412.
Koudelka J, Tobrman T
RSC Adv. 2025; 15(5):3602-3606.
PMID: 39906634
PMC: 11792975.
DOI: 10.1039/d4ra08480b.
Coats J, Li S, Tanaka T, Tauro S, Sutherland C, Saurin A
Cancer Res Commun. 2024; 4(11):3013-3024.
PMID: 39470360
PMC: 11586712.
DOI: 10.1158/2767-9764.CRC-24-0408.
Biswas B, Huang Y, Craik D, Wang C
Chem Sci. 2024; 15(33):13130-13147.
PMID: 39183924
PMC: 11339801.
DOI: 10.1039/d4sc01088d.
Brauer N, Kempen A, Hernandez D, Sintim H
Eur J Med Chem. 2024; 275:116540.
PMID: 38852338
PMC: 11243610.
DOI: 10.1016/j.ejmech.2024.116540.
Drug screening in human physiologic medium identifies uric acid as an inhibitor of rigosertib efficacy.
Rawat V, DeLear P, Prashanth P, Ozgurses M, Tebeje A, Burns P
JCI Insight. 2024; 9(13).
PMID: 38815134
PMC: 11383364.
DOI: 10.1172/jci.insight.174329.
Pharmacogenomic synthetic lethal screens reveal hidden vulnerabilities and new therapeutic approaches for treatment of NF1-associated tumors.
Williams K, Larsson A, Keller B, Chaney K, Williams R, Bhunia M
bioRxiv. 2024; .
PMID: 38585724
PMC: 10996510.
DOI: 10.1101/2024.03.25.585959.
Lights and Shadows on the Cancer Multi-Target Inhibitor Rigosertib (ON-01910.Na).
Monfort-Vengut A, de Carcer G
Pharmaceutics. 2023; 15(4).
PMID: 37111716
PMC: 10145883.
DOI: 10.3390/pharmaceutics15041232.
PLK1-ELAVL1/HuR-miR-122 signaling facilitates hepatitis C virus proliferation.
Seo Y, Kang Y, Ham Y, Kim M, Kim S, Yoon S
Proc Natl Acad Sci U S A. 2022; 119(51):e2214911119.
PMID: 36512502
PMC: 9907111.
DOI: 10.1073/pnas.2214911119.
Chick Early Amniotic Fluid (ceAF) Deters Tumorigenesis via Cell Cycle Arrest and Apoptosis.
Ahmad M, Yu J, Cheng S, Khan Z, Luo Y, Luo H
Biology (Basel). 2022; 11(11).
PMID: 36358278
PMC: 9687777.
DOI: 10.3390/biology11111577.
Synthesis and antitumor effects of novel benzyl naphthyl sulfoxide/sulfone derivatives derived from Rigosertib.
Tang L, Chen T, Yang H, Wen X, Sun Y, Liu S
RSC Adv. 2022; 11(59):37462-37471.
PMID: 35496445
PMC: 9043816.
DOI: 10.1039/d1ra05226h.
Expression of FOXM1 and PLK1 predicts prognosis of patients with hepatocellular carcinoma.
Fan W, Ma H, Jin B
Oncol Lett. 2022; 23(5):146.
PMID: 35350587
PMC: 8941521.
DOI: 10.3892/ol.2022.13266.
The Polo-like kinase 1 inhibitor onvansertib represents a relevant treatment for head and neck squamous cell carcinoma resistant to cisplatin and radiotherapy.
Hagege A, Ambrosetti D, Boyer J, Bozec A, Doyen J, Chamorey E
Theranostics. 2021; 11(19):9571-9586.
PMID: 34646387
PMC: 8490521.
DOI: 10.7150/thno.61711.
The Design, Synthesis, and Biological Activities of Pyrrole-Based Carboxamides: The Novel Tubulin Inhibitors Targeting the Colchicine-Binding Site.
Boichuk S, Galembikova A, Syuzov K, Dunaev P, Bikinieva F, Aukhadieva A
Molecules. 2021; 26(19).
PMID: 34641324
PMC: 8510300.
DOI: 10.3390/molecules26195780.
Synergistic apoptotic effect of miR-183-5p and Polo-Like kinase 1 inhibitor NMS-P937 in breast cancer cells.
Kudo M, Zalles N, Distefano R, Nigita G, Veneziano D, Gasparini P
Cell Death Differ. 2021; 29(2):407-419.
PMID: 34561554
PMC: 8816952.
DOI: 10.1038/s41418-021-00864-2.
Second-Generation Antimitotics in Cancer Clinical Trials.
Novais P, Silva P, Amorim I, Bousbaa H
Pharmaceutics. 2021; 13(7).
PMID: 34371703
PMC: 8309102.
DOI: 10.3390/pharmaceutics13071011.
Efficacy of rigosertib, a small molecular RAS signaling disrupter for the treatment of -mutant colorectal cancer.
Zhou X, Xiao Q, Fu D, Zhang H, Tang Y, He J
Cancer Biol Med. 2021; .
PMID: 34347396
PMC: 8832955.
DOI: 10.20892/j.issn.2095-3941.2020.0532.
Programmed cell death, redox imbalance, and cancer therapeutics.
Dai X, Wang D, Zhang J
Apoptosis. 2021; 26(7-8):385-414.
PMID: 34236569
DOI: 10.1007/s10495-021-01682-0.
Anti-tumor effects of rigosertib in high-risk neuroblastoma.
Radke K, Hansson K, Sjolund J, Wolska M, Karlsson J, Esfandyari J
Transl Oncol. 2021; 14(8):101149.
PMID: 34118691
PMC: 8207190.
DOI: 10.1016/j.tranon.2021.101149.
Therapeutic Targeting PLK1 by ON-01910.Na Is Effective in Local Treatment of Retinoblastoma.
Ma H, Nie C, Chen Y, Li J, Xie Y, Tang Z
Oncol Res. 2021; 28(7):745-761.
PMID: 33573708
PMC: 8420894.
DOI: 10.3727/096504021X16130322409507.